IPM chemotherapy in renal cell cancer
Author Information
Author(s): Shamash J, Steele J P, Wilson P, Nystrom M, Ansell W, Oliver R T D
Primary Institution: St Bartholomew's Hospital
Hypothesis
The study aims to evaluate the effectiveness of IPM chemotherapy in patients with renal cell carcinoma who have failed cytokine therapy.
Conclusion
IPM chemotherapy offers modest but real symptomatic benefits in cytokine refractory renal cancer.
Supporting Evidence
- One out of 31 patients had a complete response to therapy.
- 61% of patients with symptoms at the start of treatment showed improvement.
- The median progression-free interval was 4.4 months.
- Patients with a symptomatic response had improved survival compared to those without.
- 39% of patients were progression-free at 6 months.
Takeaway
This study tested a new chemotherapy combination for kidney cancer patients who didn't respond to other treatments, and some patients felt better after the treatment.
Methodology
This was a phase II single institution study assessing symptomatic and radiological response rates and progression-free survival in patients with metastatic RCC after cytokine therapy.
Potential Biases
The study was conducted at a single institution, which may limit the generalizability of the findings.
Limitations
The study had a small sample size and only two-thirds of patients completed quality-of-life assessments.
Participant Demographics
The study included 33 patients, predominantly male (29 out of 33), with a median age of 51 years.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website